• Refine Query
  • Source
  • Publication year
  • to
  • Language
  • 2
  • 1
  • Tagged with
  • 3
  • 3
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • About
  • The Global ETD Search service is a free service for researchers to find electronic theses and dissertations. This service is provided by the Networked Digital Library of Theses and Dissertations.
    Our metadata is collected from universities around the world. If you manage a university/consortium/country archive and want to be added, details can be found on the NDLTD website.
1

What is the importance of age at menarche on adult height relative to other known factors?

Kacerosky, Pamela M. 01 December 2011 (has links)
Objectives: To analyze the association between age at menarche, as a measure of sexual maturation, and adult height from ten published studies. Methods: Compared published measurements of age at menarche, adult height, and within-sample relationships observed in ten studies, for women from several societies and socioeconomic backgrounds, living in the 20th century, Results: In these studies, early maturers were taller during pre-puberty, but had shorter adult height then later maturers. Late maturers experience a longer period of pre-pubertal growth and a delayed age of peak height velocity, leading to an extended overall time of growth, until adult stature was obtained. Conclusions: Improved living conditions and energy balance increase childhood growth rate, and are associated with an earlier puberty, and shorter duration of growth. In developed countries duration of growth may play an increasingly important role in adult stature.
2

Preditores do ganho estatural em crianças nascidas pequenas para a idade gestacional tratadas com hormônio do crescimento humano recombinante / Height gain predictors in children born small for gestational age treated with recombinant human growth hormone

Aragão, Luciana Felipe Férrer 18 October 2016 (has links)
INTRODUÇÃO: Crianças nascidas pequenas para a idade gestacional (PIG) possuem risco aumentado de apresentar baixa estatura na vida adulta. O benefício do tratamento com rhGH (recombinant human growth hormone) está bem estabelecido nas crianças nascidas PIG e com inadequação do catch up de crescimento, sendo importante estudar as variáveis preditoras de ganho estatural nesses indivíduos. OBJETIVO: Avaliar resposta terapêutica e variáveis clínicas associadas à recuperação do crescimento em dois anos de tratamento com rhGH em um grupo de crianças nascidas PIG. MÉTODOS: Foram selecionadas 35 crianças nascidas PIG em uso de rhGH há pelo menos dois anos e avaliadas as seguintes variáveis: sexo, idade gestacional, SDS de peso ao nascimento, SDS de comprimento ao nascimento, índice ponderal ao nascimento, idade cronológica no início do tratamento, SDS de estatura-alvo, dose de rhGH, relação entre idade óssea e idade cronológica, delta SDS de IGF-I. RESULTADOS: A média do SDS de estatura teve um incremento significante de 0,55 SDS (p < 0,01) e 0,86 SDS (p < 0,01), no primeiro e segundo anos de tratamento com rhGH, respectivamente. A dose de rhGH foi identificada como preditora de ganho estatural após um ano de tratamento, enquanto o SDS de comprimento ao nascimento e a idade gestacional se mostraram preditoras de crescimento após dois anos de rhGH. CONCLUSÃO: Foi confirmada uma resposta de crescimento positiva ao tratamento com rhGH nas crianças nascidas PIG sem catch up de crescimento nos primeiros dois anos de vida. A avaliação de características individuais ao nascimento e ao início do rhGH, assim como a identificação das variáveis preditoras do crescimento, são importantes na decisão e otimização do tratamento / INTRODUCTION: Children born small for gestational age (SGA) are at increased risk for short stature in adulthood. Treatment benefits with rhGH (recombinant human growth hormone) is well established in children born SGA and inadequate growth catch up, therefore it is very importante to study height gain predictors in these individuals. OBJECTIVE: To evaluate therapeutic response and clinical variables associated with growth recovery in two years of rhGH treatment in a group of children born SGA. METHODS: Thirty-five children born SGA in use of rhGH for at least two years were selected and the following variables were evaluated: gender, gestational age, birth weight SDS, birth length SDS, birth weight index, chronological age at the beginning of treatment, target-height SDS, rhGH dose, chronological age and bone age relation, and delta IGF-I SDS. RESULTS: The mean height SDS had a significant increase of 0.55 SDS (p < 0.01) and 0.86 SDS (p < 0.01) in the first and second year of treatment with rhGH, respectively. The rhGH dose was identified as a height gain predictor after one year of treatment, while birth length SDS and gestational age were predictors of growth gain after two years of rhGH. CONCLUSION: A positive growth response to rhGH treatment was confirmed in children born SGA with no growth catch up in their first two years of life. Evaluation of individual characteristics at birth and in the beginning of rhGH treatment, as well as the identification growth predictors, are important for the decision and treatment optimization
3

Preditores do ganho estatural em crianças nascidas pequenas para a idade gestacional tratadas com hormônio do crescimento humano recombinante / Height gain predictors in children born small for gestational age treated with recombinant human growth hormone

Luciana Felipe Férrer Aragão 18 October 2016 (has links)
INTRODUÇÃO: Crianças nascidas pequenas para a idade gestacional (PIG) possuem risco aumentado de apresentar baixa estatura na vida adulta. O benefício do tratamento com rhGH (recombinant human growth hormone) está bem estabelecido nas crianças nascidas PIG e com inadequação do catch up de crescimento, sendo importante estudar as variáveis preditoras de ganho estatural nesses indivíduos. OBJETIVO: Avaliar resposta terapêutica e variáveis clínicas associadas à recuperação do crescimento em dois anos de tratamento com rhGH em um grupo de crianças nascidas PIG. MÉTODOS: Foram selecionadas 35 crianças nascidas PIG em uso de rhGH há pelo menos dois anos e avaliadas as seguintes variáveis: sexo, idade gestacional, SDS de peso ao nascimento, SDS de comprimento ao nascimento, índice ponderal ao nascimento, idade cronológica no início do tratamento, SDS de estatura-alvo, dose de rhGH, relação entre idade óssea e idade cronológica, delta SDS de IGF-I. RESULTADOS: A média do SDS de estatura teve um incremento significante de 0,55 SDS (p < 0,01) e 0,86 SDS (p < 0,01), no primeiro e segundo anos de tratamento com rhGH, respectivamente. A dose de rhGH foi identificada como preditora de ganho estatural após um ano de tratamento, enquanto o SDS de comprimento ao nascimento e a idade gestacional se mostraram preditoras de crescimento após dois anos de rhGH. CONCLUSÃO: Foi confirmada uma resposta de crescimento positiva ao tratamento com rhGH nas crianças nascidas PIG sem catch up de crescimento nos primeiros dois anos de vida. A avaliação de características individuais ao nascimento e ao início do rhGH, assim como a identificação das variáveis preditoras do crescimento, são importantes na decisão e otimização do tratamento / INTRODUCTION: Children born small for gestational age (SGA) are at increased risk for short stature in adulthood. Treatment benefits with rhGH (recombinant human growth hormone) is well established in children born SGA and inadequate growth catch up, therefore it is very importante to study height gain predictors in these individuals. OBJECTIVE: To evaluate therapeutic response and clinical variables associated with growth recovery in two years of rhGH treatment in a group of children born SGA. METHODS: Thirty-five children born SGA in use of rhGH for at least two years were selected and the following variables were evaluated: gender, gestational age, birth weight SDS, birth length SDS, birth weight index, chronological age at the beginning of treatment, target-height SDS, rhGH dose, chronological age and bone age relation, and delta IGF-I SDS. RESULTS: The mean height SDS had a significant increase of 0.55 SDS (p < 0.01) and 0.86 SDS (p < 0.01) in the first and second year of treatment with rhGH, respectively. The rhGH dose was identified as a height gain predictor after one year of treatment, while birth length SDS and gestational age were predictors of growth gain after two years of rhGH. CONCLUSION: A positive growth response to rhGH treatment was confirmed in children born SGA with no growth catch up in their first two years of life. Evaluation of individual characteristics at birth and in the beginning of rhGH treatment, as well as the identification growth predictors, are important for the decision and treatment optimization

Page generated in 0.0824 seconds